Impact of l-carnitine on levels of myocardial damage and inflammation biomarkers after percutaneous coronary intervention

Evaluating the effect of L Carnitine administration on post percutaneous coronary intervention levels of Troponin I as a myocardial damage and high-sensitive C-Reactive Proteins as an Inflammatory markers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201302088698N10

Enrollment

100

Registered

2013-03-08

Start date

2013-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease. Myocardial ischemia followed by decreased oxygen to the myocardium

Interventions

Intervention 1: In the first group of patients, at 24 hour before catheterization 3 g L - carnitine (1 g every 8 hours) is given and lasts for up to 48 hour later. blood samples at baseline ¸24 and 48

Treatment - Drugs

In the first group of patients, at 24 hour before catheterization 3 g L - carnitine (1 g every 8 hours) is given and lasts for up to 48 hour later. blood samples at baseline ¸24 and 48 hour after cath

Medication will not be given to patients in the control group. Patients blood sample is collected at baseline and 24 hour after catheterization.Patients blood sample is collected at baseline ¸24 and 4

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Patients with ischemic heart disease that have more than 50 percent occlusion in angiography findings and candidates for elective Pecrcutaneous Coronary Intevention.Exclusion criteria: cardiogenic shock;ST Elevation Myocardial Infarction;pregnant and lactating womens;patients under 18 years;immunologic or hematologic disorders;current infection;chronic kidney disease;serum creatinine above 2.5 mg/dl;hypothyroidism;epilepsy or convulsion;chronic liver disease;cancer

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
High sensitive C--Reactive protein. Timepoint: baseline¸24 and 48 hours after. Method of measurement: Elisa kit.;Troponin I. Timepoint: baseline¸24 and 48 hours after. Method of measurement: Elisa kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hajhossein Talasaz

Tehran University of Medical Sciences

atalasaz@razi.tums.ac.ir+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026